Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported Q2 2026 financial results and business updates, highlighting the initiation of two Phase 3 trials (FOCUS 1 and FOCUS 2) for RAP-219 in focal onset seizures. The company remains on track for topline Phase 2 results in bipolar mania later in 2026 and is progressing other pipeline candidates including a long-acting inject…